Predicting complications in liver tumor treatment
Part of Cancer, Digestive system clinical trials.
This trial uses a special scan to predict liver problems after surgery or ablation for liver tumors. It aims to help doctors personalize care and avoid complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can make your own medical decisions.
- You have one or more liver tumors (suspected or confirmed).
- Your treatment team has planned a local treatment, such as surgery to remove part of the liver or an ablation procedure.
- You are having a major liver resection (leaving less than 40% of your liver), or a smaller resection/ablation with lower liver function due to cirrhosis, fibrosis, past chemotherapy, or certain liver diseases.
- You are not allergic to Technetium-99m or albumin.
- You do not have pulmonary hypertension, and if female, you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses special CT scans to create a map of your liver's blood vessels before surgery. The goal is to predict if your liver might fail after part of it is removed, so doctors can better plan your care.
This trial uses a special type of MRI scan to see if doctors can predict how well a liver cancer treatment (called TACE) will work for you. The scan may help doctors understand your treatment response better.
This study looks at whether special scans can help doctors better predict how aggressive a person's liver cancer (hepatocellular carcinoma) will be, especially right after surgery. If you are planning to have surgery to remove the tumor as your first treatment, this trial might be a good fit.
This study looks at liver metastases treated with a procedure that destroys tumors (ablation) and then checks tumor tissue right away. The team wants to see whether the tissue results can guide immediate retreatment to better control cancer in the liver.
This trial uses a special PET scan tracer (zirconium-labelled girentuximab) to see if it can find and track certain liver, bile duct, and pancreatic/intestinal neuroendocrine tumors. It may help doctors better understand your cancer and guide treatment decisions.
This study tests a new type of imaging scan (called 68Ga-NYM207 PET/CT) that may help doctors better find and understand liver cancer. You would receive the scan once to see if it helps doctors plan your treatment or monitor your cancer.
Hear when a new Hepatic Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.